UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

79,517

102,779

154,169

46,316

65,000

D

D

D

D

D

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

\$ 108.49

\$ 106.59

\$ 106.59

\$ 86.25

\$ 67.46

Units

Stock Option

Buy) Stock

Option

Buy) Stock

Option

Buy) Stock Option

(Right to

(Right to

(Right to

Buy) Stock

Buy) Stock Option

(Right to

(Right to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Evchange Act of 1934 or Section 30(b) of the

	ontinue. See tion 1(b).	i neu pe	isuant to Section					Comp		_			r or Seen	on 30(n) 0	i tiic				
(Print or Typ	e Responses	;)																	
1. Name and Address of Reporting Person * Kummeth Charles R. (Last) (First) (Middle)				2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
				3. Date of Earliest Transaction (Month/Day/Year) 08/18/2018								Year)		X Director10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer					
SCHAIIM	IBLIDG II	(Street)		4. If Am	endı	men	t, Da	ite Ori	ginal	Filed(Month/I	Day/Year)		X_ Form filed by	One Reporting	up Filing(Chec Person Reporting Persor		Line)	
(City)		(State)	(Zip)				Ta	ble I -	- Non-	-Deriv	vative	Securition	es Acquire	ed. Disposed	l of, or Ben	eficially Ow	ned		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)			Execution any	. Deemed ecution Date, i		, if	3. Trai	nsactio	(A		. Securities Acquired A) or Disposed of (D) Instr. 3, 4 and 5)		5. Amount of Securities Ben Owned Following Reported Transaction(s) (Instr. 3 and 4)		Beneficially ed		of Inc	7. Nature of Indirect Beneficial Ownership	
				(Wolldiv Da		ay/ 1 car)	ai)	Cod	le	V A	amoun	(A) or	Price	msu. 3 and -	')		or Indirect (I) (Instr. 4)		
Common	Stock		08/18/2018					F		1	,338	D	\$ 180.5	2,176 (1)			D		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Transaction 3A. Deemed			(e.g., puts, calls, wa 4. Transaction of Code Deri			6. Da Expir	xpiration Date Month/Day/Year)				Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owner Form of Deriva Securit Direct or Indi	ship of Botive Oy: (I: (D) rect		
				Cod	le '			(D)	Date Exerc	cisable	Expi	iration	Title	Amount or Number of Shares					
Restricted Stock Units	(2)								9	(3)		<u>(3)</u>	Commo Stock	24,979		24,979	D		
Restricted Stock Units	(2)								ا	<u>(4)</u>		<u>(4)</u>	Commo Stock	21,291		21,291	D		
Restricted Stock	<u>(2)</u>								١	<u>(5)</u>		<u>(5)</u>	Commo	16,918		16,918	D		

<u>(7)</u>

<u>(3)</u>

<u>(8)</u>

<u>(8)</u>

08/07/2022

08/18/2023

08/18/2023

04/01/2021

04/01/2020

Stock

Common

Stock

Stock

Stock

Common

Stock

Common

Stock

Common 102,779

Common 154,169

79,517

46,316

65,000

Option (Right to	\$ 67.46			<u>(8)</u>	04/01/2020	Common Stock	50,000	50,000	D	
Buy) Stock Options (Right to buy)	\$ 177.32			<u>(9)</u>	08/08/2025	Common Stock	60,222	60,222	D	
Stock Options (Right to buy)	\$ 177.32			<u>(5)</u>	08/08/2025	Common Stock	90,334	90,334	D	
Stock Options (Right to buy)	\$ 125.05			<u>(4)</u>	08/09/2024	Common Stock	117,342	117,342	D	
Stock Options (Right to buy)	\$ 125.05			(10)	08/09/2024	Common Stock	78,228	78,228	D	
Stock Options (Right to buy)	\$ 94.35			(8)	08/12/2021	Common Stock	66,849	66,849	D	

Reporting Owners

Donostino Como None / Addisor	Relationships								
Reporting Owner Name / Address	Director	10% Owner	Officer	Other					
Kummeth Charles R. 425 MARTINGALE ROAD SUITE 2050 SCHAUMBURG, IL 60173-2213	X		Chief Executive Officer						

Signatures

/s/ Brenda S. Furlow, attorney in fact for Charles R. Kummeth pursuant to Power of Attorney previously filed	08/31/2018
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021.
- (10) Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
- (2) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (3) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (4) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (5) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (6) Vests 19,879 shares on each of 8/7/16, 8/7/17 and 8/7/18 and 19,880 shares on 8/7/19.
- (7) Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.
- (8) Fully exercisable
- (9) Vests 15,056 shares each on 8/8/2019, 8/8/202 and 15,055 shares each on 8/8/2021, 8/8/2022

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Brenda S. Furlow, James Hippel, Anna Weispfenning, Melodie R. Rose, Andrew Nick, Sarah Tucher or either of them acting alone, the undersigned's true and lawful attorneysin-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 3, Forms 4 and Forms 5 relating to beneficial ownership of securities of Bio-Techne Corporation (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of October, 2017.

/s/ Charles R. Kummeth